Login to Your Account

Shares Soar on Top-Line Results

Favorable Pancreatic Cancer Results 'JAK' Up Incyte Stock

By Marie Powers
Staff Writer

Thursday, August 22, 2013
Shares of Incyte Corp. (NASDAQ:INCY) lit up Wednesday morning after the company reported top-line results of ruxolitinib (Jakafi), which showed noticeable survival benefit in a Phase II study in refractory metastatic pancreatic cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription